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Abstract
Cigarette smoking is a significant environmental factor in the human inflammatory bowel
diseases, remarkably, conferring protection in ulcerative colitis. We previously demonstrated that
a prominent component of cigarette smoke, CO, suppresses Th17-mediated experimental colitis in
IL-10−/− mice through a heme oxygenase (HO)-1–dependent pathway. In this study, homeostatic
and therapeutic effects of CO and HO-1 were determined in chronic colonic inflammation in TCR-
α–deficient (−/−) mice, in which colitis is mediated by Th2 cytokines, similar to the cytokine
milieu described in human ulcerative colitis. TCRα−/− mice exposed to CO or treated with the
pharmacologic HO-1 inducer cobalt protoporphyrin demonstrated amelioration of active colitis.
CO and cobalt protoporphyrin suppressed colonic IL-1β, TNF, and IL-4 production, whereas
IL-10 protein secretion was increased. CO induced IL-10 expression in macrophages and in vivo
through an HO-1–dependent pathway. Bacterial products regulate HO-1 expression in
macrophages through MyD88- and IL-10–dependent pathways. CO exposure and pharmacologic
HO-1 induction in vivo resulted in increased expression of HO-1 and IL-10 in CD11b+ lamina
propria mononuclear cells. Moreover, induction of the IL-10 family member IL-22 was
demonstrated in CD11b− lamina propria mononuclear cells. In conclusion, CO and HO-1
induction ameliorated active colitis in TCRα−/− mice, and therapeutic effects correlated with
induction of IL-10. This study provides further evidence that HO-1 mediates an important
homeostatic pathway with pleiotropic anti-inflammatory effects in different experimental models
of colitis and that targeting HO-1, therefore, is a potential therapeutic strategy in human
inflammatory bowel diseases.
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Cigarette smoking is one of the most significant environmental risk factors identified in the
human inflammatory bowel diseases (IBD): Crohn's disease (CD) and ulcerative colitis
(UC). Meta-analyses showed that the risk for developing UC in current smokers is ∼40%
that of nonsmokers (1). Former smokers have ∼1.7 times increased risk for developing UC
(2). Some studies even suggested a dose response, with heavier smokers having greater
protection (1). Based on these compelling epidemiological observations, one of the
important unanswered questions in IBD is how does cigarette smoking mechanistically
mediate this protective effect?
The gaseous molecule CO is one candidate that may contribute to the beneficial association
between smoking and UC. CO is a prominent component of cigarette smoke: blood
carboxyhemoglobin levels, a measure of systemic exposure to CO, were reported to range
from 1–18% in active smokers (3). CO, best known as a toxic compound, is also produced
endogenously during normal physiology by the heme oxygenase (HO) enzymes, which
mediate the degradation of heme into equimolar quantities of CO, iron, and biliverdin. In
particular, the enzyme HO-1 and its metabolic products regulate immune responses, tissue
injury, and repair (4). We previously showed that CO ameliorates active inflammation in an
experimental model of chronic IBD, IL-10–deficient (−/−) mice, through induction of HO-1
(5).
CD4+ Th cells play a key role in the regulation of immune responses in the intestine. CD4+
T cells have been divided into functionally important subsets based on the cytokines that
they produce (6). Although these subdivisions represent a reduction of complex biology,
most applicable to the mouse, they provide a framework to understand mucosal T cell
responses in human IBD. Th1 cells produce the cytokines IFN-γ and IL-2. Th1 cells are a
hallmark of cell-mediated immunity, necessary for the eradication of intracellular pathogens
and the development of long-term immunity against infectious agents (6). Numerous mouse
models of IBD are characterized by an overabundance of intestinal Th1 cytokines. CD was
initially described as a prototype Th1-mediated chronic inflammatory disorder,
characterized by mucosal granulomas (the histological hallmark of a Th1 response),
increased expression of IFN-γ, as well as increased IL-12, a cytokine necessary for Th1
development (7). However, the discovery of the cytokine IL-23, which shares a common
p40 subunit with IL-12, led to a paradigm shift in our understanding of inflammatory
responses in IBD (8). IL-23, unlike IL-12, promotes a distinct CD4+ T cell activation
profile, the Th17 cell, characterized by the production of the cytokine IL-17. A pivotal role
for IL-23 and Th17 cells was demonstrated in experimental IBD models, such as the
IL-10−/− mouse, and recent genetic and immunologic findings highlight the importance of
this pathway in human IBD (9).
Th2 cells produce the cytokines IL-4, IL-5, and IL-13. These cytokines provide help for B
cell Ab production, and are involved in host defense against extracellular helminthic
parasites in the mucosal immune system (10). Inflammation in human UC has been
characterized as mediated by Th2 cytokines. Lamina propria T cells from UC patients
produce IL-13 and IL-5 and little IFN-γ (11). Although multiple experimental models of
chronic Th1/17-driven intestinal inflammation have been elucidated, few have been
described in which chronic disease occurs in a Th2 cytokine milieu. Mice with targeted
disruption of the TCRα gene (TCRα−/−) perhaps most closely recapitulate the colonic Th2
signature in human UC. IL-4 and IL-1β play important roles in the development of colitis in
TCRα−/− mice (12).
Our previous work showed that CO and HO-1 induction ameliorates Th17-mediated colonic
inflammation in IL-10−/− mice (5). To model the protective effects of cigarette smoking in
human UC, CO and the HO-1 pathway were studied in a murine model with immunologic
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similarities to UC. We demonstrate the anti-inflammatory effects of CO and HO-1 induction
in spontaneous Th2-mediated colitis in TCRα−/− mice.
Materials and Methods
Mice
Wild-type (WT), TCRα−/−, and IL-10−/− mice were obtained from The Jackson Laboratory.
Hmox1−/− mice were provided by Leo Otterbein (Harvard Medical School, Boston, MA).
All mice used in this study were on the C57BL/6 background and matched for age and sex
in all experiments. Animals were housed in accordance with guidelines from the American
Association for Laboratory Animal Care and Research Protocols and by the Institutional
Animal Care and Use Committee of the University of Pittsburgh and the University of North
Carolina Schools of Medicine.
CO exposure
Mice or macrophages were exposed to compressed air or CO at a concentration of 250 ppm,
as previously described (5). Briefly, CO at a concentration of 1% (10,000 ppm) was mixed
with compressed air before delivery into the exposure chamber. Flow into the animal
chamber was maintained at a rate of 12 l/min and into the cell-culture chamber at a rate of 2
l/min. The cell-culture chamber was humidified and maintained at 37°C. A CO analyzer
(Interscan) was used to measure CO levels continuously in the chambers. The CO-releasing
molecule-186 (ALF186) was a generous gift from Alfama (Porto Salvo, Portugal) and was
injected i.p. twice a week for 2 wk. Control mice were injected with an inactive form of
ALF186 (iALF186) that does not possess CO-releasing capacity. At the end of CO
exposure, cardiac blood samples (0.2 ml) were taken immediately after mice were sacrificed
to measure carboxyhemoglobin (HbCO) using a hemoximeter (OSM3; Radiometer
Copenhagen). Doses of ALF186 were extensively optimized because hypoxia can become a
confounding factor at HbCO levels ≥20% (13). HbCO levels were uniformly <20% in all
experiments using CO gas and ALF186.
Pharmacologic inhibition and induction of HO-1
Tin protoporphyrin (SnPP) and cobalt protoporphyrin (CoPP) (Frontier Scientific Porphyrin
Products, Logan, UT) were dissolved in sodium hydroxide; a final pH of 7.4 was achieved
by adding hydrochloric acid and further dilution with PBS. Because of light sensitivity,
SnPP and CoPP were prepared in dim light, light protected, and freshly made before
injection.
TLR ligands and cytokines
Ultrapure TLR ligands (Invivogen, San Diego, CA), LPS, synthetic bacterial lipopeptide
(sBLP), flagellin, and CpG oligodeoxynucleotides (CpG) were dissolved in endotoxin-free
water at concentrations described in the Results. IL-10 (PeproTech, Rocky Hill, NJ) was
dissolved in endotoxin-free water.
Cytokine ELISAs
Linco Cytokine-16 plex Mouse ELISA was performed for IL-4, IL-1β, IL-10, TNF, and
IL-17 ((Millipore, Billerica, MA), per the manufacturer's instructions. Murine IL-10 was
measure with cytokine-specific immuno-assay kits (R&D Systems, Minneapolis, MN).
Real-time RT-PCR analysis
Quantitative real-time PCR, using SYBR Green Master Mix (Applied Biosystems, Bedford,
MA), was performed on an HT-7900 (Applied Biosystems, Bedford, MA), as previously
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published (14). The following primer sequences were used: Hmox1: forward, 5′-
CCAGAGTTTCCGCATACAACC-3′, reverse, 5′-TCTCTGGACACCTGACCCTTCG-3′;
β-actin: forward, 5′-AGCCATGTACGTAGCCATCCAG-3′, reverse, 5′-
TGGCGTGAGGGAGAGCATAG-3′; Il10: forward, 5′-
GTCATCGATTTCTCCCCTGTG-3′, reverse, 5′-CCTTGTAGACACCTTGGTCTTGG-3′;
and Il22: forward, 5′-GGTGCCTTTCCTGACCAAAC-3′, reverse, 5′-
TTTCACTGTCTCCTTCAGCCTTC-3′.
Western immunoblots
Western blots were performed on whole-cell extracts, as described (15). HO-1 Abs were
from Stressgen (Plymouth Meeting, PA); NF-E2–related factor 2 (Nrf2) and β-actin Abs
were from Abcam (Cambridge, MA).
Bone marrow-derived macrophages
Bone marrow-derived macrophages (BMMs) were cultured as described previously (5).
Colonic tissue explant cultures
Colonic tissue fragments (0.5 g dry weight) were processed, as previously described (14).
Tissue-fragment supernatants were collected after 24 h for cytokine ELISAs.
Isolation of colonic macrophages
Lamina propria mononuclear cells (LPMCs) were isolated from mouse colon by an
enzymatic method, followed by Percoll (GE Healthcare, Piscataway, NJ) density-gradient
centrifugation, as previously described (16). LPMCs were further separated into CD11b+
cells using anti-CD11b microbeads (Miltenyi Biotec, Auburn, CA). Purity was >90% by
flow cytometric analysis.
Flow cytometry
Splenic, mesenteric lymph node, and colonic cells were isolated, as previously described
(17), and stained with the B cell marker FITC anti-mouse B220 and cell surface marker PE
anti-mouse CD1d (1B1) (eBioscience, San Diego, CA). In other experiments, cells were
stained extracellularly with FITC-conjugated anti-CD4+ (RM4-5), fixed and permeabilized
with Cytofix/Cytoperm solution (BD Pharmingen, San Jose, CA), and stained intracellularly
with allophycocyanin-conjugated anti-Foxp3 (FJK-16s). Colonic LPMCs from TCR−/− mice
exposed to CO or injected with ALF186, as well as control mice (air-exposed and iALF186-
treated mice), were labeled with Abs against macrophage lineage and activation markers
(CD14, F4/80, CD86, and CD80; eBioscience, San Diego, CA). Dead cells were excluded
with propidium iodide staining. Samples were acquired on a FACSCalibur (Becton
Dickinson), and data were analyzed with Cell-Quest Pro software (BD Biosciences, San
Jose, CA).
Histology
Colitis scores (0–4) were determined by a staff pathologist who was blinded to the
experimental protocol using the criteria reported by Berg et al. (18). Twenty separate
microscopic fields (original magnification ×100) were evaluated for each mouse by a
pathologist (A.R.S.) blinded to the treatment groups.
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Statistical significance for data subsets from experiments performed in cells was assessed by
the two-tailed Student t test. Statistical significance for in vivo data subsets was assessed by
the Mann–Whitney U test (SPSS, Chicago, IL) with Bonferroni correction.
Results
CO exposure ameliorates active colitis in TCRα−/− mice
TCRα−/− mice were exposed to 250 ppm of CO from 12–16 wk of age (n = 10) and
compared with a control group (n = 10) exposed to ambient air. Mice in both treatment
groups were matched for age, sex, and initial body weight. CO-exposed mice showed an
increase in body weight compared with mice housed in ambient air (Fig. 1A). Assessment of
histological improvement was performed by a pathologist blinded to treatment groups. CO-
exposed mice demonstrated significantly reduced histologic inflammation (Fig. 1B,
Supplemental Fig. 1).
We next determined whether CO exposure affects colonic cytokine expression in TCRα−/−
mice. Colonic explant cultures from TCRα−/− mice exposed to CO in vivo for 4 wk
produced less IL-1β, IL-4, TNF, and IL-17 (Fig. 1C, 1D), correlating with histological
improvement. CO treatment in vivo also resulted in increased colonic IL-10 secretion
compared with explant cultures from air-exposed TCRα−/− mice (Fig. 1C).
Because IL-10 is an important regulatory cytokine, correlations between CO exposure and
colonic IL-10 induction were further explored. Ten-week-old TCRα−/− mice were divided
into three groups: group 1 was exposed to CO (250 ppm) for 4 wk, group 2 was exposed to
air for 4 wk, and group 3 was exposed to CO for 2 wk and then transferred to ambient air for
2 wk. Mice exposed to CO demonstrated increased secretion of IL-10 in colonic explants.
Mice transferred from CO exposure to air after 2 wk showed intermediate IL-10 secretion,
with more colonic IL-10 compared with air-exposed mice but less than mice continually
exposed to CO (Fig. 1E). These findings suggested that CO may ameliorate inflammation
through induction of IL-10. Furthermore, because IL-10 secretion was still increased 2 wk
after removing mice from CO, CO may induce a durable change in a cell population that
secretes IL-10 in the colon.
CO induces IL-10 and HO-1 in colonic CD11b+ LPMCs
To elucidate potential mechanisms through which CO ameliorates experimental colitis,
TCRα−/− mice were treated i.p. with ALF186 (30 mg/kg) and iALF186 (30 mg/kg) twice
weekly for 2 wk. Colonic CD11b+ LPMCs, predominantly representing a macrophage cell
population (14), were isolated from both groups, and Hmox1 and Il10 expression were
analyzed. Hmox1 was induced in CD11b+ and CD11b− LPMCs in ALF186-treated TCRα−/−
mice compared with iALF186-treated mice (Fig. 2A), with the most significant induction in
CD11b+ cells. Interestingly, markedly increased Il10 expression was demonstrated in
CD11b+ LPMCs, but not in CD11b− LPMCs, from ALF186-treated mice compared with
iALF186-treated mice (Fig. 2B). No differences were observed in expression of surface
markers (F4/80, CD80, CD86, and CD14) in CD11b+ LPMCs from TCRα−/− mice treated
with ALF186 or iALF186 (Supplemental Fig. 2A). Similar results were obtained for Hmox1
and Il10 expression in LPMCs from ALF186-treated WT mice, with the exception that Il10
induction was also demonstrated in the CD11b− LPMC population (Supplemental Fig. 3),
possibly reflecting increased numbers of CD4+ Foxp3+ lamina propria T regulatory cells in
WT mice compared with TCRα−/− mice (see later discussion; Supplemental Fig. 1C).
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Another member of the IL-10 family of cytokines, IL-22, was shown to dampen innate
mucosal inflammatory responses and attenuate colitis in TCRα−/− mice (19). LPMCs from
ALF186-treated TCRα−/− mice demonstrated significantly more IL-22 (Il22) expression
compared with iALF186-treated mice, predominantly in the CD11b− LPMC population, but
in CD11b+ cells as well (Fig. 2C).
Regulatory CD4+ Foxp3+ T and CD11d+ B cells were demonstrated to be a source of
intestinal IL-10 production and have important anti-inflammatory roles in murine IBD (19).
However, no differences in the numbers of CD1d+ B cells in LPMCs were found between
iALF186- and ALF186-treated TCRα−/− mice (Supplemental Fig. 2B). Interestingly, a
marked decrease in the numbers of splenic CD4+ Foxp3+ T cells was observed in TCRα−/−
mice compared with WT mice (Supplemental Fig. 2C), and Foxp3+ cells were undetectable
in LPMCs from TCRα−/− mice (data not shown). These results suggested that CO may be
protective in experimental colitis through induction of IL-10 and HO-1, specifically in
CD11b+ LPMCs.
CO induces IL-10 in macrophages through induction of HO-1
To further elucidate regulation of IL-10 by CO in macrophages, WT and TCRα−/− BMMs
were stimulated with LPS in CO (250 ppm) or ambient air for 24 h. As previously described
(13), CO-augmented LPS stimulated IL-10 secretion in WT BMMs (Fig. 3A) (5). CO also
augmented IL-10 secretion from LPS-stimulated TCRα−/− BMMs (Fig. 3B). However, in
LPS-activated BMMs from HO-1–deficient (Hmox1−/−) mice, CO failed to induce IL-10
secretion (Fig. 3C), suggesting that CO augments IL-10 secretion through an HO-1–
dependent signaling pathway. Moreover, WT BMMs incubated with ALF186 (100 μg/ml)
for 3 h demonstrated significantly increased basal Hmox1 and Il10 expression compared
with iALF186 BMMs (Fig. 3D, 3E).
HO-1 induction recapitulates immunomodulatory effects of CO in vivo
To understand the role of HO-1 in the anti-inflammatory effects of CO in vivo, TCRα−/−
mice were treated with a pharmacological inducer of HO-1, CoPP (5 mg/kg i.p.), twice a
week for 2 wk and compared with vehicle (DMSO)-treated controls. CoPP treatment
resulted in improved histological scores compared with vehicle treatment (Fig. 4A).
Moreover, colonic explant cultures revealed decreased IL-4 (Fig. 4B), IL-1β, TNF, and
IL-17 (Fig. 4C) secretion in CoPP-treated TCRα−/− mice. CoPP treatment also resulted in
robust induction of Hmox1 expression in colonic CD11b− and CD11b+ LPMC populations
(Fig. 4D). Colonic CD11b+ LPMCs were the primary source of IL-10 secretion from CoPP-
treated TCRα−/− mice, because less IL-10 expression was observed in CD11b− cells (Fig.
4E). These results strongly implicated CD11b+ LPMCs as the primary source of IL-10 in
TCRα−/− mice and important targets for the immunomodulatory effects of CO and HO-1.
Next, to address whether immunomodulatory effects of CO are mediated by HO-1 in vivo,
TCRα−/− mice were treated i.p. with ALF186, with or without the HO-1 inhibitor SnPP.
ALF186-treated mice demonstrated reduced histologic inflammation compared with
ALF186+SnPP-treated mice (Fig. 5A). Importantly, CD11b+ LPMCs from ALF186+SnPP-
treated TCRα−/− mice expressed significantly less Il10 than did CD11b+ LPMCs from
ALF186-treated mice (Fig. 5B). Likewise, CD11b− and CD11b+ LPMCs from
ALF186+SnPP-treated TCRα−/− mice demonstrated lower Il22 expression than did LPMCs
from ALF186-treated mice (Fig. 5C). These findings demonstrated that the anti-
inflammatory effects of CO are abrogated in the presence of an HO-1 inhibitor.
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LPS and IL-10 regulate HO-1 expression in macrophages
Because HO-1 is required for the protective effects of CO, we next studied HO-1 (Hmox1)
regulation in macrophages. BMMs from WT and IL-10−/− mice were stimulated with LPS,
with or without IL-10, and expression of Hmox1 mRNA and HO-1 protein was determined.
IL-10−/− BMMs demonstrated decreased expression of Hmox1 compared with WT BMMs.
Addition of rIL-10 restored Hmox1 mRNA and protein expression in LPS-activated
IL-10−/− BMMs and augmented Hmox1 expression in WT BMMs (Fig. 6A, 6B). Moreover,
incubation of WT BMMs with an IL-10 Ab inhibited LPS-induced expression of HO-1.
These results demonstrated that LPS and IL-10 are regulators of HO-1 in macrophages.
TLRs recognize specific molecular patterns present in a broad range of microbial pathogens.
TLR activation uses a common signal-transduction pathway initiated by the adaptor protein
MyD88. To further elucidate TLR-mediated induction of HO-1, WT and MyD88−/− BMMs
were stimulated with MyD88-dependent (sBLP, LPS, flagellin, and CpG DNA) bacterial
ligands. Interestingly, sBLP, LPS, flagellin, and CpG DNA induced HO-1 expression in WT
BMMs but not in MyD88−/− BMMs (Fig. 6C). Addition of rIL-10 restored HO-1 expression
in MyD88−/− BMMs, suggesting that IL-10–induced expression of HO-1 in macrophages is
independent of TLR/MyD88-signaling pathways. As previously reported, TLR-mediated
IL-10 expression, another MyD88-dependent gene, was abrogated in MyD88−/− BMMs
(Supplemental Fig. 4).
The transcription factor Nrf2 is a critical regulator of HO-1 through binding to antioxidant
response elements (20). In the absence of MyD88, Nrf2 protein expression in macrophages
was also markedly reduced (Fig. 6C). These results elucidated a novel regulatory circuit,
with MyD88-dependent Hmox1 expression by bacterial products, in part through Nrf2, and
MyD88-independent regulation by IL-10.
Discussion
In summary, CO exposure ameliorates chronic Th2-mediated colitis in TCRα−/− mice.
Immunomodulatory effects of CO were recapitulated by pharmacologic HO-1 induction.
Moreover, pharmacologic inhibition of HO-1 blocked the protective effects of CO on colitis,
suggesting that in vivo, CO mechanistically requires HO-1 function. CO and HO-1
induction resulted in increased colonic IL-10 expression prominently in CD11b+ LPMCs,
with consequent inhibition of inflammatory cytokines. We previously demonstrated that CO
ameliorated colitis in IL-10−/− mice (5). IL-10−/− mice exhibit a Th17-mediated immune
pathology. The protective effects of CO in IL-10−/− mice were attributed, in part, to
inhibition of the common p40 subunit of the inflammatory cytokines IL-12 and IL-23 (5).
Our current study elucidated the anti-inflammatory effects of CO and the HO-1 pathway in
TCRα−/− mice characterized by a distinctly different immunopathogenesis, with increased
colonic Th2 cytokine expression that, to some extent, recapitulates the colonic inflammatory
cytokine milieu in human UC (12). This study further elucidated pleiotropic
immunomodulatory effects of CO and the HO-1 pathway. There are now illustrations of
therapeutic applications of this pathway (5, 21, 22) in multiple experimental models of IBD
mediated by divergent immune mechanisms. Given the genetic, immunologic, and clinical
heterogeneity of the human IBDs, the therapeutic benefit of CO and HO-1 in numerous
preclinical models suggests potentially broad applications in patients.
Notably, in TCRα−/− mice, CO- and HO-1–mediated inhibition of inflammation correlated
with increased levels of the anti-inflammatory cytokine IL-10. Cross-talk between CO/HO-1
and IL-10 regulation may underlie the homeostatic function of each modality. Lee and Chau
(23) demonstrated that IL-10 induced the expression of HO-1 via a p38 MAPK-dependent
pathway. IL-10–induced expression of HO-1 also requires activation of STAT-3 (24).
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Moreover, HO-1 may be an important downstream mediator of the anti-inflammatory effects
of IL-10 in macrophages. HO-1 activity and the generation of endogenous CO were
necessary for IL-10–dependent inhibition of TNF expression (25). Likewise, LPS-activated
macrophages overexpressing HO-1 or exposed to CO demonstrated reduced TNF
production, whereas IL-10 secretion was enhanced (26). Interestingly, we demonstrated that
LPS stimulated HO-1 expression in WT BMMs, but not IL-10−/− BMMs, and blocking
IL-10 diminished LPS-activated HO-1 expression. Hence, IL-10 is a cofactor for HO-1
induction by TLR ligands. Moreover, Hmox1 induction occurred through MyD88-dependent
(bacterial products) and -independent (IL-10) pathways. LPS and inflammatory cytokines
(IL-1β and TNF) are well described as potent inducers of HO-1, and several studies linked
NF-κB and AP-1 transcription factors in this response (27, 28). However, given the absence
of a clearly identified functional NF-κB element, how NF-κB promotes Hmox1 gene
transcription is a matter of speculation (29–31). Nrf2, a basic leucine zipper transcription
factor, is involved in cellular protection against oxidative stress through antioxidant
response element-directed induction of multiple detoxifying and antioxidant enzymes,
including HO-1 (20). We demonstrated defective induction of Nrf2 in MyD88−/− BMMs,
suggesting a mechanism for how TLR signaling may affect Hmox1 transcription.
HO-1 was also shown to exert its protective effect in experimental asthma through a
mechanism mediated by IL-10 expression in CD4+CD25+Foxp3+ T regulatory cells (32). In
vivo CO exposure ameliorated intestinal injury induced by LPS or ischemia–reperfusion.
Mucosal levels of IL-10 were shown to be increased in CO-exposed mice (33). Similarly,
CO-releasing molecules promoted resolution of acute pancreatic inflammation in rats, which
correlated with increases in local IL-10 expression (34). CO was also shown to augment
local IL-10 and afford protection in other models of inflammation, including sepsis, renal
injury, and diabetes (35–37).
Activated macrophages are an abundant source of IL-10 (38). CO augments basal and LPS-
induced IL-10 secretion from WT and TCRα−/− BMMs. Specifically, TCRα−/− mice treated
with CO and CoPP demonstrated a specific increase in IL-10 secretion exclusively from
CD11b+ LPMCs, which include a predominant resident macrophage population. These
findings expand upon an important homeostatic role for IL-10–producing colonic
macrophages, which acted on T regulatory cells to maintain expression of Foxp3 in a T cell
adoptive-transfer model of murine colitis (39).
Several regulatory B cell populations have been characterized in TCRα−/− mice. A subset of
regulatory B cells was identified as an important source of IL-10 and was responsible for
inhibiting IL-1β and ameliorating colitis (40). However, we could not discern any difference
in the numbers of CD1d+ MLNs from ALF186-treated TCRα−/− mice compared with
iALF186-treated mice. An IL-12–producing regulatory B cell subset that develops in the
presence of IL-10 was also shown to be involved in the regulation of colonic inflammation
in this model (41). During CO exposure and pharmacologic HO-1 induction in vivo, IL-10 is
almost exclusively detected in the CD11b+ LPMC fraction. These findings suggested that
CO and HO-1 induction, mediated in part through IL-10, has anti-inflammatory effects that
extend beyond the induction of previously described regulatory B cell populations in this
model.
Colonic Foxp3+ cells were not detected in ALF186- or iALF186-treated TCRα−/− mice.
Moreover, a significant deficiency of splenic CD4+Foxp3+ T cells was observed in TCRα−/−
mice compared with WT mice. The TCR was shown to be involved in the development of
CD4+Foxp3+ T cells (42); however, the influence of TCRα-chain repertoire on the
development of CD4+ Foxp3+ T cells has not been analyzed. TCRα-chain expression is not
essential for CD4+CD25+ T cell development, but its effect on Foxp3 expression remains
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unknown (43). Although the purpose of our study was not to discern T regulatory cell
development in TCRα−/− mice, taken as a whole, our results suggested that the predominant
source of IL-10 in LPMCs from TCRα−/− mice, and therefore a target for CO and HO-1
induction, resides in the CD11b+ population and not Foxp3+ T cells.
We unexpectedly detected a Th17-cytokine signature in colonic explants from TCRα−/−
mice with abundant levels of IL-17. The IL-17–producing cell population(s) remain(s) to be
determined. Given recent reports, it is interesting to speculate that γδ T cells may be a source
of IL-17 (44). Interestingly, IL-17 levels decreased following CO exposure or HO-1
induction, correlating with histologic improvement. Recently, the IL-10 family member
IL-22, expressed by Th17 cells, was demonstrated to ameliorate colitis in TCRα−/− mice
(19). CO-treated TCRα−/− mice demonstrated significant increases in IL-22 mRNA
expression in CD11b− LPMCs, consistent with previous studies suggesting that that
nonmacrophage-derived IL-22 may also be involved in the protective effects of CO/HO-1.
Notably, IL-22 is a potent inducer of IL-10 (19). The description of a Th17 signature in
TCRα−/− mice also substantiated this as a model for human UC, in which the same genetic
associations within the IL-23/Th17 pathway confer susceptibility to CD and UC (45).
Likewise, current biological interventions that inhibit TNF are approved for the treatment of
moderate to severe UC (46). CO and pharmacological induction of HO-1 resulted in a
significant decrease in TNF secretion in TCRα−/− colons, which may also mediate
therapeutic effects.
To our knowledge, these results are the first to characterize anti-inflammatory properties of
CO and HO-1 in a Th2-mediated model of chronic colonic inflammation. The anti-
inflammatory effects of CO are attributed to the induction of HO-1 and highlight the broad
impact of these pathways in intestinal inflammation. HO-1 induction correlated with
increased IL-10 and IL-22 expression in vivo, which may be relevant anti-inflammatory
mechanisms of this pathway, because both cytokines were previously determined to have a
protective role in colonic inflammation in TCRα−/− mice (19, 41). It remains to be
determined whether HO-1 induction mediates downstream anti-inflammatory effects in
colitis models through increased enzymatic activity and production of endogenous metabolic
products, including CO, or through other mechanisms. Nonetheless, these experiments
demonstrated that HO-1 is a central regulator of intestinal homeostasis through pleiotropic
mechanisms and that understanding these pathways are of mechanistic and therapeutic
relevance in human IBD.
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CO ameliorates Th2-mediated colitis in TCRα−/− mice. TCRα−/− mice were housed in
ambient air or a chamber maintaining a constant concentration of CO at 250 ppm (n = 10
each) from 12–16 wk of age. A, CO-exposed mice gained more weight than did air-exposed
mice. B, Colitis scores were significantly decreased in CO-exposed mice compared with
control mice. Results are presented as the sum total of four averaged scores from five
regions of the large intestine graded by a pathologist blinded to the groups using a standard
scoring system. Bars represent mean ± SEM of 10 mice/group. C, Spontaneous protein
secretion determined in 24-h supernatants from colonic explants from CO-exposed (black
bars) and air-exposed (white bars) TCRα−/− mice. Spontaneous IL-10 and IL-4 were
measured by cytokine-specific ELISA. D, IL-1β, TNF, and IL-17 secretion were assessed by
Linco 16-multiplex cytokine assay. Each result represents the mean ± SEM of triplicate
assays. E, Ten-week-old TCRα−/− mice were divided into three groups: exposed to CO (250
ppm; black bar) for 4 wk, exposed to air for 4 wk (white bar), or exposed to CO for 2 wk
and then transferred to ambient air housing conditions for 2 wk (gray bar). Spontaneous
IL-10 secretion was measured in full-length colonic cell-free supernatants using cytokine-
specific IL-10 ELISA. Results represent mean ± SEM from three experiments (n = 3 mice/
group). *p < 0.05, **p < 0.01 versus air-exposed mice.
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CO upregulates Hmox1 and Il10 expression in colonic CD11b+ LPMCs from TCRα−/−
mice. LPMCs were isolated from colons of TCRα−/− mice treated with iALF186 (n = 4) or
ALF186 (n = 4). LPMCs were further separated into CD11b− and CD11b+ cells and
analyzed for Hmox1 (A), Il10 (B), and Il22 (C) expression by real-time RT-PCR. Results
were normalized to β-actin. Bars represent mean ± SEM of triplicate cultures from pooled
LPMCs from four mice per group. *p < 0.05 versus iALF186-treated CD11b+ LPMCs.
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CO induces IL-10 in murine macrophages via the HO-1 pathway. BMMs from WT (A),
TCRα−/− (B), or Hmox1−/− (C) mice were cultured in CO (250 ppm, black bars) or ambient
air (white bars). Following activation with LPS (1 μg/ml), IL-10 protein secretion was
assayed in 24-h supernatants by ELISA. WT BMMs were incubated with iALF186 (100 μg/
ml) or ALF186 (100 μg/ml) for 3 h, and Hmox1 (D) and Il10 (E) expression was analyzed
by real-time RT-PCR. Results were normalized to β-actin and represent the mean ± SEM of
triplicate assays from three independent experiments. *p < 0.05 versus air-exposed or
iALF186-treated BMMs.
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The HO-1 inducer CoPP ameliorates colitis in TCRα−/− mice. Twelve-week-old TCRα−/−
mice were treated with i.p. injection of CoPP (5 mg/kg, twice a week for 2 wk) (n = 8), and
control mice were treated with DMSO vehicle i.p. (n = 12). A, CoPP-injected mice had less
severe colitis. B, Spontaneous protein secretion determined in 24-h supernatants from
colonic explants from CoPP-treated (5 mg/kg) and vehicle-treated (DMSO) TCRα−/− mice.
C, Spontaneous IL-4 was determined by cytokine-specific ELISA, and IL-1β, TNF, and
IL-17 secretion were determined by Linco 16-multiplex cytokine assay. Bars represent mean
± SEM from 12 mice per group. D, LPMCs were isolated from colons of TCRα−/− mice
treated with CoPP (black bars) and vehicle (white bars), separated into CD11b− and CD11b+
cells, and analyzed for Hmox1 expression by real-time RT-PCR, with results normalized to
β-actin. E, IL-10 secretion was determined by ELISA. Each result represents the mean ±
SEM of triplicate assays from four mice/treatment group. *p < 0.05 versus vehicle-treated
mice.
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Hmox1 function is required for amelioration of colitis and Il10 and Il22 upregulation by CO
in TCRα−/− mice. A, Colitis scores were significantly higher in iALF-186 (n = 6) ALF186+
SnPP (50 μM/kg twice/weekly for 2 wk) (n = 6) treated mice compared with mice treated
with ALF186 alone (n = 6). B and C, LPMCs were isolated from colons of TCRα−/− mice
treated with ALF186 (n = 6) or ALF186+SnPP (n = 6). They were separated into CD11b−
and CD11b+ cells and analyzed for Il10 (B) and Il22 (C) expression by real-time RT-PCR.
Results were normalized to β-actin. Bars represent mean ± SEM triplicate cultures from
pooled LPMCs from six mice per group. *p < 0.05 versus iALF186-treated TCRα−/− mice
and CD11b+ LPMCs.
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Regulation of HO-1 in macrophages is IL-10 and MyD88 dependent. A, WT and IL-10−
BMMs were stimulated with LPS alone (100 ng/ml) or with LPS plus IL-10 (10 ng/ml) for
12 h. Total RNA was isolated and analyzed for Hmox1, and β-actin mRNA expression was
detected by real-time RT-PCR. Results are expressed as mean ± SEM from three
independent experiments. *p < 0.05 versus LPS-treated WT BMMs. B, WT and IL-10−/−
BMMs were stimulated with LPS (100 ng/ml) in the presence of IL-10 (10 ng/ml) for 24 h
after initial preincubation with anti–IL-10 Ab (10 μg/ml) for 1 h. HO-1 protein was analyzed
by Western blotting. Data are representative of five independent experiments with similar
results. C, WT and MYD88−/− BMMs were stimulated with LPS (100 ng/ml), CpG (1 μM),
sBLP (100 ng/ml), flagellin (10 ng/ml), or IL-10 (10 ng/ml) for 24 h. HO-1 and Nrf2 protein
was analyzed by Western blotting. Data are representative of three independent experiments.
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